# Parkinsonâ€™s Disease Treatment Landscape (2024â€“2025)

## ğŸ“Œ í”„ë¡œì íŠ¸ ê°œìš”
**Parkinsonâ€™s Disease (PD) ì¹˜ë£Œì œ ì‹œì¥ Landscape ë¶„ì„ (2024â€“2025)** 
ì£¼ìš” ëª©ì ì€ **ë°ì´í„° ìˆ˜ì§‘ â†’ êµ¬ì¡°í™” â†’ ì‹œê°í™” â†’ ì¸ì‚¬ì´íŠ¸ ë„ì¶œ**ì˜ ì „ ê³¼ì •ì„ ì§ì ‘ ìˆ˜í–‰í•˜ì—¬  
í—¬ìŠ¤ì¼€ì–´ ì‹œì¥ ë¶„ì„ ì—­ëŸ‰ê³¼ ë°ì´í„° ê¸°ë°˜ ìŠ¤í† ë¦¬í…”ë§ ëŠ¥ë ¥ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤.  

---

## ğŸ“Š ë°ì´í„° ì†ŒìŠ¤
- **ê¸€ë¡œë²Œ ì‹œì¥ ë³´ê³ ì„œ**: IQVIA, EvaluatePharma, McKinsey ë“±
- **Regulatory ë‰´ìŠ¤ & ë³´ë„ìë£Œ**: FDA, EMA, PR Newswire, ê¸°ì—… IR ë°œí‘œ
- **í•™ìˆ  ë¬¸í—Œ & ë¦¬ë·°**: Nature, PubMed, PMC
- **ê¸°ì—… ì›¹ì‚¬ì´íŠ¸**: AbbVie, Amneal, BlueRock, Medtronic, SynAgile

---

## ğŸ“‘ ë¶„ì„ êµ¬ì¡°

1. **Market Overview**
   - ê¸€ë¡œë²Œ PD ì¹˜ë£Œì œ ì‹œì¥ ê·œëª¨ ($5â€“6B, CAGR ~4%)  
   - Neuroscience íˆ¬ì/ë”œ íŠ¸ë Œë“œ  

2. **Current Standard of Care**
   - Levodopa/Carbidopa, Dopamine agonists, MAO-B & COMT inhibitors, A2A antagonist  
   - Device-based therapy (LCIG, DBS)

3. **Recent Approvals (2024â€“2025)**
   - AbbVie **VYALEV / PRODUODOPA** (continuous SC infusion)  
   - Amneal **CREXONT (ER levodopa)**  
   - Istradefylline (A2A antagonist, OFF management niche)  

4. **Pipeline Highlights**
   - AbbVie **tavapadon** (D1/D5 partial agonist, NDA 2025 ì˜ˆì •)  
   - BlueRock/Bayer **bemdaneprocel** (DA neuron cell therapy, Phase 2 ì¤€ë¹„)  
   - Gene therapy & digital biomarkers  

5. **Competitive Landscape**
   - **AbbVie**: full-spectrum PD strategy (infusion + D1/D5 agonist)  
   - **Amneal**: oral ER convenience focus  
   - **Neurocrine/Kyowa Kirin**: COMT/A2A niche (OFF ê´€ë¦¬)  
   - **Medtronic**: adaptive DBS (BrainSense, gold standard in advanced PD)  
   - **SynAgile**: DopaFuse non-invasive continuous delivery  

6. **Key Themes & Unmet Needs**
   - OFF/ON fluctuations â†’ infusion & ER dominance  
   - Disease-modifying therapies (cell/gene therapy)  
   - Digital biomarkers & real-world endpoints  
   - Non-motor symptoms (cognitive, mood, sleep)  

7. **Insights**
   - **Data**: Continuous infusion + oral ER = OFF episode ì§‘ì¤‘ ê³µëµ  
   - **Market Size**: PD Tx $5â€“6B, neurology R&D rebound  
   - **Commercial Drivers**: í™˜ì ì„¸ë¶„í™” + delivery í˜ì‹  + RWE & digital endpoints  

---

## ğŸ“‚ Repository êµ¬ì„±
- `pd_landscape.xlsx`: ë°ì´í„° í…Œì´ë¸” ë° ì •ë¦¬ë³¸
- `README.md`: í”„ë¡œì íŠ¸ ì†Œê°œ ë° ìš”ì•½ ì¸ì‚¬ì´íŠ¸

---

## ğŸ“ˆ ì‚¬ìš© íˆ´ & ì—­ëŸ‰
- **Excel**: ë°ì´í„° ì •ë¦¬ ë° êµ¬ì¡°í™”
